415 results
8-K
EX-99.1
WINT
Windtree Therapeutics, Inc.
20 Aug 24
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
4:30pm
milestone payments
Other liabilities
Deferred tax liabilities
Total liabilities
Mezzanine Equity:
Series B redeemable preferred stock, $0.001 par value … before income taxes
Income tax expense
Net loss per common share
Basic and diluted
Weighted average number of common shares outstanding
Basic and diluted
8-K
EX-4.1
WINT
Windtree Therapeutics, Inc.
29 Jul 24
Entry into a Material Definitive Agreement
8:33am
the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided … that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any
8-K
EX-10.1
p59esj
29 Jul 24
Entry into a Material Definitive Agreement
8:33am
8-K
EX-4.1
bag6ht8j2yj lf8p6r
22 Jul 24
Entry into a Material Definitive Agreement
9:25am
8-K
EX-10.1
pg0dl0ji9x9a7
22 Jul 24
Entry into a Material Definitive Agreement
9:25am
8-K
EX-3.1
4zsjw94
22 Jul 24
Entry into a Material Definitive Agreement
9:25am
8-K
EX-4.1
azrjer0j09dyh
10 Jul 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:53pm
8-K
EX-4.2
rhcvryjl
10 Jul 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:53pm
8-K
EX-4.2
0sh2 g6gxr0i26o7zm9
1 Jul 24
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-10.1
03t fbemi
1 Jul 24
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-4.1
pnb95gaeb
1 Jul 24
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-99.1
jyvd j5ii6o
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am